These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35963101)

  • 1. Immediate reinfection with Omicron variant after clearance of a previous SARS-CoV-2 infection.
    Mencacci A; Gili A; Camilloni B; Bicchieraro G; Spaccapelo R; Bietta C; Stracci F
    J Infect Public Health; 2022 Sep; 15(9):983-985. PubMed ID: 35963101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of SARS-CoV-2 Omicron reinfection resulting in a significant immunity boost in a paediatric patient affected by B-cell acute lymphoblastic leukemia.
    Scutari R; Fox V; De Ioris MA; Fini V; Granaglia A; Costabile V; Colagrossi L; Russo C; Mastronuzzi A; Locatelli F; Perno CF; Alteri C
    BMC Infect Dis; 2023 Mar; 23(1):133. PubMed ID: 36882724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS CoV-2 reinfection rate is higher in the Omicron variant than in the Alpha and Delta variants.
    Özüdoğru O; Bahçe YG; Acer Ö
    Ir J Med Sci; 2023 Apr; 192(2):751-756. PubMed ID: 35711013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response and severity of Omicron BA.5 reinfection among individuals previously infected with different SARS-CoV-2 variants.
    Li L; Xie Z; Li Y; Luo M; Zhang L; Feng C; Tang G; Huang H; Hou R; Xu Y; Jia S; Shi J; Fan Q; Gan Q; Yu N; Hu F; Li Y; Lan Y; Tang X; Li F; Deng X
    Front Cell Infect Microbiol; 2023; 13():1277880. PubMed ID: 38188634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.
    Shiwa-Sudo N; Sakai Y; Iwata-Yoshikawa N; Watanabe S; Yamada S; Kuroda Y; Yamamoto T; Shirakura M; Fujisaki S; Miyazaki K; Miura H; Nagata S; Fukushi S; Maeda K; Hasegawa H; Suzuki T; Nagata N
    J Virol; 2023 Jan; 97(1):e0136622. PubMed ID: 36633406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review.
    Arabi M; Al-Najjar Y; Sharma O; Kamal I; Javed A; Gohil HS; Paul P; Al-Khalifa AM; Laws S; Zakaria D
    BMC Infect Dis; 2023 Jun; 23(1):432. PubMed ID: 37365490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reinfection rate and disease severity of the BA.5 Omicron SARS-CoV-2 lineage compared to previously circulating variants of concern in the Canary Islands (Spain).
    Ciuffreda L; Lorenzo-Salazar JM; García-Martínez de Artola D; Gil-Campesino H; Alcoba-Florez J; Rodríguez-Pérez H; Íñigo-Campos A; Salas-Hernández J; Rodríguez-Nuñez J; Muñoz-Barrera A; Valenzuela-Fernández A; Díez-Gil O; González-Montelongo R; Flores C
    Emerg Microbes Infect; 2023 Dec; 12(1):2202281. PubMed ID: 37039029
    [No Abstract]   [Full Text] [Related]  

  • 9. Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.
    Carazo S; Skowronski DM; Brisson M; Barkati S; Sauvageau C; Brousseau N; Gilca R; Fafard J; Talbot D; Ouakki M; Gilca V; Carignan A; Deceuninck G; De Wals P; De Serres G
    Lancet Infect Dis; 2023 Jan; 23(1):45-55. PubMed ID: 36152671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time from prior infection: a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022.
    Vicentini M; Venturelli F; Mancuso P; Bisaccia E; Zerbini A; Massari M; Cossarizza A; De Biasi S; Pezzotti P; Bedeschi E; Giorgi Rossi P; ;
    Euro Surveill; 2023 Mar; 28(13):. PubMed ID: 36995374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omicron SARS-CoV-2 variant of concern: A review on its transmissibility, immune evasion, reinfection, and severity.
    Mohsin M; Mahmud S
    Medicine (Baltimore); 2022 May; 101(19):e29165. PubMed ID: 35583528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
    Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
    Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of symptoms, comorbidities, and reinfections in individuals infected with Wild-Type SARS-CoV-2, Delta, or Omicron variants: a comparative study in western Mexico.
    Peña Rodríguez M; Hernández Bello J; Vega Magaña N; Viera Segura O; García Chagollán M; Ceja Gálvez HR; Mora Mora JC; Rentería Flores FI; García González OP; Muñoz Valle JF
    Front Public Health; 2023; 11():1149795. PubMed ID: 37181688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022.
    Hall VJ; Insalata F; Foulkes S; Kirwan P; Sparkes D; Atti A; Cole M; de Lacy E; Price L; Corrigan D; Brown CS; Islam J; Charlett A; Hopkins S;
    J Infect; 2024 Jan; 88(1):30-40. PubMed ID: 37926119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replacement dynamics and the pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2.
    Ward T; Glaser A; Overton CE; Carpenter B; Gent N; Seale AC
    Epidemiol Infect; 2022 Dec; 151():e32. PubMed ID: 36535802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 immune response and reinfection in vaccinated Maya and mestizo in Southeast of Mexico.
    Monteón V; León-Pérez F; Ancona-León JG; Gutiérrez-Torres G
    Salud Publica Mex; 2023 Dec; 66(1, ene-feb):14-16. PubMed ID: 38065105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live-virus neutralization of the omicron variant in children and adults 14 months after SARS-CoV-2 wild-type infection.
    Stich M; Benning L; Speer C; Garbade SF; Bartenschlager M; Kim H; Jeltsch K; Tabatabai J; Niesert M; Janda A; Renk H; Elling R; Hoffmann GF; Kräusslich HG; Müller B; Bartenschlager R; Tönshoff B
    J Med Virol; 2023 Mar; 95(3):e28582. PubMed ID: 36794653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
    Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
    Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis.
    COVID-19 Forecasting Team
    Lancet; 2023 Mar; 401(10379):833-842. PubMed ID: 36930674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.